Francischi J N, Dias M F, Rocha O A, de Abreu Castro M S, Kiyomi Funayama Tatsuo M A, Farinelli P, Pacheco C M, Ferreira-Alves D L, Sirois P
Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais, Brazil.
Int Arch Allergy Immunol. 1996 Apr;109(4):398-406. doi: 10.1159/000237269.
An intravenous injection of Sephadex beads has been used to induce lung inflammation and bronchial hyperreactivity in small animals. In the present study, we injected Sephadex beads (0.3-5.5 mg/paw) into rat paws and followed the resulting inflammation plethysmometrically. Our results show that Sephadex beads induced a significant and dose-dependent increase in the hindpaw volume at 5 min; it was maximal at 30-60 min and declined at 4 h. However, the paw volume remained significantly increased for up to 21 days. The initial 4-hour-oedema was confirmed by histopathology of the paw tissues, but the persistent increase in paw volume was related to a chronic inflammatory (granulomatous) response. The Sephadex-induced oedema was predominantly due to serotonin (5-HT) release since specific antagonists such as methysergide (1 mg/kg) and pizotifen (0.1-2 mg/kg) administered both systemically and locally were able to inhibit the oedema (10-100 microgram/paw) as could pretreatment with compound 48/80. In addition, platelet-activating factor (PAF) was also shown to be involved, since systemic pretreatment using the specific PAF antagonist BN 52021 (1 mg/kg) was able to inhibit the increase in paw volume induced by Sephadex. Effective doses of indomethacin (2 mg/kg), L-NAME (1 mg/kg), pyrilamine (1-2 mg/kg), ondansetron (1 mg/kg) and HOE 140 (1 mg/kg) did not affect the Sephadex-induced oedema, thus ruling out the participation of prostaglandins, nitric oxide, histamine, 5-HT3 receptors and bradykinin in its development. Since the late increases in paw volume induced by Sephadex were reduced by pretreatment of the animals with the immunosuppressive drugs rapamycin and dexamethasone but not cyclosporin, our results also suggested that distinct immunological pathways may be involved in the modulation of the chronic phase of inflammation induced by Sephadex beads in rat paws.
静脉注射葡聚糖珠已被用于在小动物中诱导肺部炎症和支气管高反应性。在本研究中,我们将葡聚糖珠(0.3 - 5.5毫克/爪)注射到大鼠爪中,并通过体积描记法跟踪由此产生的炎症。我们的结果表明,葡聚糖珠在5分钟时可使后爪体积显著且呈剂量依赖性增加;在30 - 60分钟时达到最大值,并在4小时时下降。然而,爪体积在长达21天的时间内仍显著增加。爪组织的组织病理学证实了最初4小时的水肿,但爪体积的持续增加与慢性炎症(肉芽肿性)反应有关。葡聚糖诱导的水肿主要是由于5-羟色胺(5-HT)释放,因为全身和局部给予的特异性拮抗剂如甲基麦角新碱(1毫克/千克)和苯噻啶(0.1 - 2毫克/千克)能够抑制水肿(10 - 100微克/爪),化合物48/80预处理也有此效果。此外,血小板活化因子(PAF)也被证明参与其中,因为使用特异性PAF拮抗剂BN 52021(1毫克/千克)进行全身预处理能够抑制葡聚糖诱导的爪体积增加。有效剂量的吲哚美辛(2毫克/千克)、L-精氨酸甲酯(1毫克/千克)、吡苄明(1 - 2毫克/千克)、昂丹司琼(1毫克/千克)和HOE 140(1毫克/千克)均不影响葡聚糖诱导的水肿,因此排除了前列腺素、一氧化氮、组胺、5-HT3受体和缓激肽在其发展过程中的参与。由于用免疫抑制药物雷帕霉素和地塞米松预处理动物可减少葡聚糖诱导的后期爪体积增加,但环孢素则无此作用,我们的结果还表明,不同的免疫途径可能参与了葡聚糖珠诱导的大鼠爪炎症慢性期的调节。